Two of our devices have pre-clinical applications that can be very useful for drug development and research
The RatCAP is a miniature PET scanner allows whole brain imaging in fully conscious rats for the first time. By far the world's smallest and lightest PET scanner, it is the only PET system able to be mounted on the head of a lab rat, allowing for the first-time functional images of the whole brain during the rat's typical behavior. Research PET centers will be eager to acquire this unique tool, and pharmaceutical companies will be interested in using it in drug development, especially for neurological applications in which anesthesia can interfere with the results. Even universities without access to the full infrastructure of PET will see this as a low-cost entry into the growing field of PET imaging.
The small-animal PET insert for MRI is an accessory for commercial small animal MRI systems to provide simultaneous PET and MRI imaging. An ultra compact and MRI-compatible PET scanner, designed to fit inside existing commercial small-animal MRI systems to provide simultaneous functional and structural imaging with PET and MRI.
Our other two devices provide great opportunities in the clinical human diagnostic and treatment markets
The wrist scanner is a practical non-invasive way to bring quantitative PET to the bedside. It’s an imaging instrument that measures radioactivity levels in the blood, potentially eliminating the need for invasive arterial blood sampling in human PET research, and thus facilitating the use of enhanced quantitative procedures in the clinic. The wrist scanner will enable personalized protocols in medical treatment, like for chemotherapy. Your physician will know during your first treatment whether it is working or not, and if it needs to be adjusted. This will save time, and lives.
The Breast PET-MRI is a compact MRI-compatible PET system able to retrofit clinical MRI systems to simultaneously image breast tumors with PET and MRI, thereby adding to the clinical confidence of MRI findings (which have a high false positive rate), and reducing unnecessary biopsy by directing attention to the most suspicious lesions.
These products will enhance pharmaceutical development of new cancer drugs, and drugs for neurological disorders like Alzheimers or Parkinsons. Furthermore, our devices for the clinical market will help us detect cancer more accurately and treat it more effectively.
The founders of SynchroPET are interested in a profitable company, but almost as important, we are interested in making a difference.